Atlas Trials

Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Clinical trial NCT04720807 · UNKNOWN

Trial details

NCT number
NCT04720807
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Platinum-resistant Recurrent Ovarian Cancer
Start date
2020-09-01
Primary completion
2022-08-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.